News

Merck Triggers The Race to Replace Cubist

December 8, 2014

A real healthcare crisis has been in the works for the last half-century and it has nothing to do with the cost of healthcare, although you could argue it has something to do with the price of it.

Continue Reading

And The Winners Are Actavis, Allergan And Ackman

November 17, 2014

With White Knight Actavis standing in its corner, Allergan was able to outmaneuver Valeant Pharmaceuticals and Bill Ackman’s hedge fund, Pershing Square Capital, breaking a seven-month siege of the company.

Continue Reading

Can Actavis Break The Siege Of Allergan?

November 13, 2014

The Allergan saga just became the stuff of George R.R. Martin novels.

Continue Reading

Does the GI Bill even work?

November 11, 2014

Over the last 12 months, failures in the VA healthcare system have dominated reporting about the Veterans Administration.

Continue Reading

Stopping Ebola: Mali Matters; Maine and Manhattan Don’t

October 30, 2014

This has been an attention-grabbing week for Ebola in America.

Continue Reading

WBB Securities Acts as Financial Advisor to NeoStem, Inc. on $20MM Debt Facility

September 29, 2014

NeoStem announces $20 million term loan financing from Oxford Finance LLC

Continue Reading

WBB Securities Sponsors BioCentury’s 21st Annual NewsMakers Conference

September 29, 2014

Executive Teams of Emerging Biotech Companies Present to Investor Community

Continue Reading

Why the Ebola Crisis Won’t End Without Military Intervention

September 16, 2014

Ebola has evoked our worst nightmares as it continues to outrun containment efforts.

Continue Reading

Retrophin, Gilead, and Our Healthcare Values

September 12, 2014

Have you ever wondered how our society values innovation, how it rewards breakthrough discoveries? Most people say that it’s the price we place on new drugs that show how much we value the breakthrough.

Continue Reading

Analyst Interview with Steve Brozak: Big-Picture Biotech Stocks Rule the Future

September 8, 2014

Steve Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow’s healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors’ attention.

Continue Reading